COX-2 Archives
Reversing stress-related anxiety
Dec. 20, 2019—Inhibiting COX-2 — an enzyme associated with inflammation — could provide a novel therapeutic approach for stress-related psychiatric disorders.
COX-2 ‘conjugate’ may slow growth of some tumors: study
Jan. 19, 2017—More than a decade after the anti-inflammatory drugs Vioxx and Bextra were pulled from the market because of a heightened risk of heart attack and stroke in some patients, COX-2 inhibitors may be on the verge of a comeback, this time as anti-cancer agents.
Imaging probe for retinal disease
Oct. 12, 2016—An imaging probe developed at Vanderbilt detects retinal inflammation early and may allow therapeutic intervention to prevent blindness.
COX-2 blocker could help PTSD
May. 12, 2016—COX-2 inhibitors – used clinically to reduce inflammation and pain – may find new applications for treating PTSD and other stress-related psychiatric disorders like major depression.
The yin and yang of COX-2
Oct. 2, 2015—New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.
Lit up COX-2 cancer probe
Jun. 17, 2015—A new imaging probe developed by Vanderbilt investigators enhances tumor visibility and has broad applications in diagnosing and monitoring patients with cancer.
Low-dose aspirin’s protective effect in cancer explained
Oct. 2, 2014—For years, scientists have known that regular aspirin use may reduce the risk of cancer.
Vanderbilt scientists discover potential new way to treat anxiety
Aug. 5, 2013—Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural “endocannabinoids” without gastrointestinal side effects, Vanderbilt University scientists will report next week.
Urine biomarker for colon cancer?
Mar. 10, 2012—A molecule detectable in urine may be helpful in diagnosing colon cancer.
